Powder: -20°C for 3 years | In solvent: -80°C for 2 years
Dasatinib 是一种具有口服活性的，ATP 竞争性的，双重Src/Bcr-Abl 抑制剂，抑制Bcr-Abl 和Src 的IC50分别为
| 产品描述 | Dasatinib is a potent inhibitor of the Bcr-Abl and Src family (IC50s: 0.6, 0.8, 79 and 37 nM for Abl, Src, c-Kit, and c-KitD816V, respectively). |
| 靶点活性 | c-Kit (wt):79 nM (cell free), Abl:0.6 nM (cell free), c-Kit (D816V):37 nM (cell free), Src:0.8 nM (cell free) |
| 体外活性 | Dasatinib (BMS-354825) potently inhibited wild-type Abl kinase and all mutants except T315I over a narrow range (IC50 ≤ 1.7 nmol/L). BMS-354825 (IC50: 0.8 nmol/L) displayed 325-fold greater potency compared with imatinib against cells expressing wild-type Bcr-Abl [1]. BMS-354825 binds 76 of 148 kinases screened at 10 μM, 47 of them with Kd 200 nM [2]. Dasatinib inhibits the kinase activity of KITD816V with comparable efficiency to wild-type KIT (IC50 of 37 and 79 nM, respectively) in in vitro kinase experiments. Dasatinib suppresses the growth of HMC-1.1V560G+, D816V- cells in the low nanomolar range. Furthermore, dasatinib retains activity against HMC-1.2V560G+, D816V+ cells [3]. |
| 体内活性 | Daily treatment with dasatinib (50 mg/kg) was initiated on day 10. Using this approach, a significant inhibition of BCPAP orthotopic tumor growth was observed 6 days after treatment, which was sustained through days 23 and 29, compared with vehicle-treated mice. The BCPAP orthotopic final tumor volumes were inhibited by more than 90% in response to dasatinib treatment [4]. The in vivo PK values in rat plasma and DBS after oral administration (50 mg/kg dasatinib) were comparable. The mean AUC value at 10 mg/kg from the historical report was about1200 ng·h/mL while themeanAUCvalue at 50 mg/kg in rat plasma from this study was about 2000 ng·h/mL [5]. |
| 激酶实验 | Kinase assays using wild-type and mutant glutathione S-transferase (GST)–Abl fusion proteins (c-Abl amino acids 220-498) were done as described, with minor alterations. GST-Abl fusion proteins were released from glutathione-Sepharose beads before use; the concentration of ATP was 5 μmol/L. Immediately before use in kinase autophosphorylation and in vitro peptide substrate phosphorylation assays, GST-Abl kinase domain fusion proteins were treated with LAR tyrosine phosphatase according to the manufacturer's instructions. After 1-hour incubation at 30°C, LAR phosphatase was inactivated by addition of sodium vanadate (1 mmol/L). Immunoblot analysis comparing untreated GST-Abl kinase to dephosphorylated GST-Abl kinase was routinely done using phosphotyrosine-specific antibody 4G10 to confirm complete (>95%) dephosphorylation of tyrosine residues and c-Abl antibody CST 2862 to confirm equal loading of GST-Abl kinase. The inhibitor concentration ranges for IC50 determinations were 0 to 5,000 nmol/L (imatinib and AMN107) or 0 to 32 nmol/L (BMS-354825). The BMS-354825 concentration range was extended to 1,000 nmol/L for mutant T315I. These same inhibitor concentrations were used for the in vitro peptide substrate phosphorylation assays. The three inhibitors were tested over these same concentration ranges against GST-Src kinase and GST-Lyn kinase [1]. |
| 细胞实验 | Ba/F3 cell lines were plated in triplicate and incubated with escalating concentrations of imatinib, AMN107, or BMS-354825 for 72 hours. Proliferation was measured using a methanethiosulfonate-based viability assay. IC50 and IC90 values are reported as the mean of three independent experiments done in quadruplicate. The inhibitor concentration ranges for IC50 and IC90 determinations were 0 to 2,000 nmol/L (imatinib and AMN107) or 0 to 32 nmol/L (BMS-354825). The imatinib concentration range was extended to 6,400 nmol/L for mutants with IC50 >2,000 nmol/L. The BMS-354825 concentration range was extended to 200 nmol/L for mutant T315I [1]. |
| 动物实验 | For in vivo studies, dasatinib (50 mg/kg) was prepared for daily oral gavage (5 d/wk) in 80 mmol/L sodium citrate buffer, pH 3.0. For the orthotopic murine model, mice were randomized on day 10 based on bioluminescence activity to receive drug or vehicle. In the metastatic murine model, mice received dasatinib or vehicle, as described earlier, starting 2 days before intracardiac injection (pretreatment), or on day 11 following randomization (posttreatment) [4]. |
| 别名 | BMS-354825, 达沙替尼 |
| 分子量 | 488.01 |
| 分子式 | C22H26ClN7O2S |
| CAS No. | 302962-49-8 |
Powder: -20°C for 3 years | In solvent: -80°C for 2 years
H2O: <1 mg/mL
Ethanol: <1 mg/mL
DMSO: 91 mg/mL (186.5 mM)
( < 1 mg/mL refers to the product slightly soluble or insoluble )
参考文献文献引用
剂量换算对于不同动物的给药剂量换算，您也可以参考 更多...
体内实验配液计算器请在以下方框中输入您的动物实验信息后点击计算，可以得到母液配置方法和体内配方的制备方法： 比如您的给药剂量是10 mg/kg，每只动物体重20 g，给药体积100 μL，一共给药动物10 只，您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法：2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL)， 如您需要配置的浓度超过该产品的溶解度，请先与我们联系。
体内配方的制备方法：取 50 μL DMSO 主液，加入 300 μL PEG300， 混匀澄清，再加 50 μL Tween 80，混匀澄清，再加 600 μL ddH2O, 混匀澄清。
计算器bottom
您可能有的问题的答案可以在抑制剂处理说明中找到，包括如何准备库存溶液，如何存储产品，以及基于细胞的分析和动物实验需要特别注意的问题。
Dasatinib 302962-49-8 Angiogenesis Apoptosis Autophagy Cytoskeletal Signaling Tyrosine Kinase/Adaptors Bcr-Abl Src c-Kit active antiproliferative CML antitumor BMS-354825 breast Inhibitor prostate BMS 354825 colon K562 WiDr 达沙替尼 PC3 orally inhibit BMS354825 inhibitor
沪公网安备 31010602006700号
